Advanced NanoTherapies, Inc’s Post

✨ We’re halfway through #ESCRS2024! Have you visited booth 6.G08 yet? Come learn about EyeMax Mono and discover how it’s revolutionising care for AMD patients. Let’s discuss how our innovative IOL can bring better vision outcomes to your practice. Don’t miss out! #EyeMaxMono #SharpviewOphthalmology #VisionCare #Eyecare #Biotech #Medtech #Lifescience

Yes you can use standard NaI , introduce at 1960, detectors for theranostics but with Starguide you will do it at a other level

Bioprocessing Professionals: Frustrated with inefficiencies and waste? This free 10-minute webinar explores how Nexcel® BIO1250, a film technology by Sealed Air, can help you achieve these goals: Reduce waste and replacement costs: Nexcel® BIO1250 extends container lifespans and minimizes over-inspection in your cell culture and cell therapy operations. Optimize your Bioprocessing workflow: Discover how Nexcel® BIO1250 can improve efficiency and cost-effectiveness. Ensure compliance with critical industry regulations: Nexcel® BIO1250 adheres to strict standards for cell culture and cell therapy. Benefit from a PFAS-free design: Nexcel® BIO1250 provides added safety and environmental responsibility. Curious to see how Nexcel® BIO1250 can transform your operations? Watch the webinar now: https://lnkd.in/e2WWBsCT? #bioprocessing #wastereduction #cellculture #celltherapy #nexcel #webinar

Learn more about the future of Total Artificial Hearts from the leader SynCardia Systems, LLC You won't want to miss this event. #STAH #USUnicornFoundation #USUF #SynCardia #MedicalInnovation #TotalArtificialHeart #MedicalDevices #heartfailure

*** Did you know? L&R and MedTECH - they belong together. We are very proud of what we have already achieved with our Suprasorb CNP Negative Pressure Therapy System! Because: medical technology can save lives. *** Today we are presenting you one of our patented special solutions for negative pressure wound therapy. The Suprasorb CNP drainage film - conceived and developed by L&R. Together WITH doctors FOR doctors. The Suprasorb CNP drainage film is inserted as a protective layer in delicate areas of the body, such as an open abdomen. It was also specially developed for this challenging scenario. There it protects the organs. At the same time, its unique structure ensures particularly effective removal of harmful exudate. An independent jury also recognized the uniqueness of our special Suprasorb CNP drainage film solution: in 2011, it was awarded the Rhineland-Palatinate Innovation Prize. And this is one of the reasons why L&R is particularly proud of it. 💪🌟👏 https://ow.ly/fQLE50U55FZ #LRMed #medtech #CNP #innovation #drainagefilm

We’re thrilled to share that our subsidiary, Kardiolytics Inc, has been granted a new patent in the United States, marking a significant milestone in our journey towards revolutionizing cardiac care. The patent, numbered US20240120110A1, recognizes our method of numerical modeling of blood flow in arteries—a vital component of our #VCAST technology. What does this mean for healthcare? 🏥 Our patented method allows for precise analysis of arterial blood flow, enabling clinicians to assess atherosclerotic plaque surface deformation and stress—an invaluable tool in diagnosing coronary artery disease. Przemek Tadla, CTO at Medicalgorithmics and COO at Kardiolytics, shares his thoughts: “This new patent underscores the medical and commercial potential of the VCAST technology. It highlights our innovation and strengthens the competitive edge and protection of our technology.” But that’s not all! 🚀 We’re also making strides in regulatory approval processes. With CE certification initiation in the EU and plans for FDA approval in the US, we’re on track to bring VCAST to patients worldwide, offering a non-invasive, hospitalization-free diagnostic solution for coronary artery disease. Stay tuned as we continue to push the boundaries of innovation in cardiac care with VCAST technology: https://lnkd.in/eSMWKcts #Medicalgorithmics #VCAST #Innovation #CardiacCare #HealthTech

From bench to bedside: Drug-Coated Balloons. “We were instrumental in launching the world’s first approved Drug-Coated Balloon device 15 years ago, and we have played a key role in the latest round of DCB launches,” shares Júlia Lleixà Calvet, PhD, Director of Business Development at Freudenberg Medical and Hemoteq AG in a recent DeviceTalks AbbottTalks podcast with Kayleen Brown. Building on this strong legacy and expertise, Julia shares her vision for the future—specifically improving outcomes for CLTI patients—and how Freudenberg Medical, alongside Hemoteq AG, will continue to support their expanding customer base on this journey. #DeviceTalks #InnovatingTogether #Medtech #DrugCoatedBalloons

Helping a client to get to their first-in-human studies with an innovative device design requires a deep understanding of user requirements and medical device development. Find out how Cambridge Design Partnership helped our client Clexio Biosciences to start their clinical trial. #Pharmaceutical #MedicalDevice #DrugDeliveryDevice

🚀 Revolutionizing Diagnostics with IPLEXMED! 🚀 IPLEXMED is at the forefront of innovation in rapid diagnostic solutions and will be showcasing their groundbreaking technology at the upcoming DxPx Conference EU'25 in Munich! ❗Problem: Chronic respiratory disease patients often face delayed diagnostics (12–24 hours), limited to hospital labs, leading to empirical treatments and increased mortality. 💡 Solution: NexaGuard by IPLEXMED – a fast, affordable diagnostic platform with graphene genosensors for multiplex detection. Delivering lab-grade results in just 20 minutes, NexaGuard integrates seamlessly into hospital workflows and includes connectivity for remote monitoring, addressing unmet healthcare needs. Meet their incredible founders Bruno Almeida,Neide Vieira, PhD, Joana Rafaela Guerreiro and Jérôme Borme learn more about their latest achievements and amazing technology. 🌟 They are currently backed by their investors PATHENA and António Murta. #Innovation #Diagnostics #MedTech #DxPx

📰 NEWS: 'VTT Leads to €32 million project on photonics for healthcare' VTT is overseeing the coordination of a project called PhotonMed, which has been provided with €32 million from the Chips JU/EU and national funding agencies. With 39 partners in 9 countries, PhotonMed aims to accelerate the uptake of research innovations in photonics-based diagnostics, surgical tools and therapeutic applications, by ensuring they are directly implementable in manufacturing. To read the full article, click the link 🔗 https://lnkd.in/eyQG_Zgj #PICMagazine #PhotonicIntegratedCircuits #news